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The development of increasingly sensitive and specific serum 
cardiac biomarkers has led a revolution in the diagnosis and 
management of acute coronary syndrome (ACS). However, although 
the troponins now in use are considered highly sensitive cardiac 
biomarkers in the general population, the interpretation of troponins 
in patients with acute kidney injury (AKI), chronic kidney disease 
(CKD) and end-stage kidney disease (ESKD) has long caused 
diagnostic uncertainty.
The metabolism and excretion of troponins are affected by changes 
in estimated glomerular filtration (eGFR) rates, making single values 
often unhelpful.1,2 Diagnosis of an acute coronary episode using 
the recommended serial measurements of cardiac biomarkers is 
more important than ever in the renal population due to the higher 
prevalence of non-ST-segment elevation MI (NSTEMI). However, 
increasing evidence shows that it is important not to disregard the 
results even in those patients in whom there is no dynamic change in 
troponin values. Studies show that the chronically elevated troponin 
concentrations seen in CKD and ESKD patients are associated with 
increased cardiovascular events and mortality.3 This careful and 
considered approach to looking at troponins means that although 
they are a useful component of the ACS diagnostic pathway, they can 
also act as a trigger for addressing cardiac risk factors in this high-
risk population.
AKI is a common diagnosis among hospitalised patients. A recent 
meta-analysis, using the Kidney Disease Improving Global Outcomes 
(KDIGO) definition of AKI, demonstrated that one in five adults 
hospitalised worldwide (21.6%) experienced AKI, and that this was 
associated with high morbidity and mortality.4 The incidence of AKI 
is increasing, particularly among the elderly, a population that also 
experiences multiple comorbidities, including a high incidence of ACS.5 
The common causes of AKI are sepsis, hypovolaemia, nephrotoxins 
and urinary obstruction. Kidney function and renal clearance change 
rapidly during the evolution of AKI to its peak and then during recovery. 
This means careful consideration is required with regard to the 
interpretation of serum biomarkers and drugs used to treat ACS that 
are metabolised and secreted by the kidneys.
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Metabolism of Cardiac Biomarkers by the Kidney
The kidneys play a major role in the metabolism and clearance of 
small peptides and proteins.6 For example, insulin concentrations 
increase with decreasing kidney function due to reduced excretion. 
Peptides and small proteins are partially filtered through the 
glomerular filtration barrier and enter the proximal tubule where 
they are reabsorbed by the megalin–cubilin complex and are 
metabolised in the lysosome.6,7 Various serum biomarkers, including 
cardiac biomarkers, are handled by the kidney in a similar manner. 
Therefore, interpretation of the serum concentrations of these 
biomarkers presents an additional challenge in the context of AKI, 
where glomerular filtration changes rapidly during on-going injury 
and then recovery. Similarly, the concentrations of these peptides are 
chronically elevated in patients with CKD and ESKD. 
Cardiac Biomarkers of Acute Coronary Syndrome
In the past 50 years, numerous serum biomarkers have been 
discovered and are now used in conjunction with ECG changes and 
clinical presentation in the diagnosis of ACS. Initially, non-specific 
markers, such as white blood cell count, were used. The first 
enzyme biomarker to be used was aspartate aminotransferase in 
the 1960s, followed by the discovery of lactate dehydrogenase and 
creatinine kinase later that decade, and the muscle/brain fraction of 
creatinine kinase (CK-MB) in the 1970s.8 However, over the past three 
decades, cardiac biomarkers, particularly troponins, have become 
increasingly sensitive and specific, and are now the cornerstone for the 
diagnosis of ACS. 
Troponins as cardiac-specific biomarkers were described for the first 
time in the late 1980s.9 Troponins T, I and C are components of the 
cardiac troponin complex, which is integral to actin–myosin interaction 
and cardiac muscle contraction.6 
Troponin C exists in the skeletal muscle and hence is not cardiac 
specific. Non-functional free subfractions of troponin move from 
the myocardial cell cytoplasm into the circulation promptly after 
myocardial injury.10 Unbound cytosolic troponin T (cTnT), which is 
released after acute injury, is approximately 6% of all troponin T pool 
in the cell, and 3% for cardiac troponin I (cTnI) pool. cTnI is a smaller 
molecule than cTnT (~187 versus 288 amino acids, respectively).10
In one study from the late 1990s, serum cardiac biomarkers were 
measured in 67 samples from 24 ESKD patients without any history 
of acute heart disease and no regional wall motion abnormalities on 
echocardiogram.11 CK-MB was increased in at least one sample in 30% 
of patients, whereas cTnT was increased in 71%. In the same study, 
troponin T was demonstrated in skeletal muscle biopsy, suggesting 
possible expression of troponin T in skeletal muscle with myopathy 
associated with ESKD.11 However, cross-reaction with the skeletal 
muscle isoform of troponin T is now considered less significant due to 
improvements in immunoassays.12
Cardiac biomarkers are integral to current diagnosis of MI. The 
universal definition of MI states that there must be an increase in 
cardiac biomarkers (preferably cardiac troponin) with at least one value 
above the 99th percentile of the upper reference limit and/or a fall in 
cardiac biomarkers along with a list of other clinical features, such as 
specific ECG or echocardiographic changes.13
Cardiac Troponins in Chronic Kidney Disease 
and End-stage Kidney Disease
Although there have been advances in the sensitivity and specificity 
of cardiac biomarkers, the interpretation of troponin in CKD and 
dialysis patients remains a challenge. Many studies have investigated 
concentrations of cardiac troponins with decreasing glomerular 
filtration. One such study explored cardiac troponin concentrations in 
489 patients referred for 51Cr EDTA or isohexol eGFR estimation due 
to any clinical indication.14 Patients were divided by the presence or 
absence of prior MI, heart failure, chronic angina or atrial fibrillation, 
and those with recent ACS were excluded. Concentrations of cTnT, 
cTnI, copeptin, N-terminal pro B-type natriuretic peptide (NT-proBNP), 
heart-type fatty acid binding protein (H-FABP) and cystatin C were 
higher in patients with increasing CKD stages, regardless of prior 
history of cardiac disease.14
Figure 1: Diagnostic Algorithm for Symptoms of Acute Coronary Syndrome in Patients with an Abnormal Renal Profile
Elevated baseline cTn*
No signicant rise† at 1,3 or 6 hours
Consider high-risk, control risk factors
Typical or atypical ACS symptoms and abnormal renal prole
Normal baseline cTn**
No signicant rise† at  1 or 3, 6 hours
ECG ST     + cTn*
Rule out ACS Treat as NSTEMI
Treat as STEMI
Normal or high baseline cTn*
AND signicant rise†† at 1, 3 or 6 hours
or new ECG or imaging ndings
Consider AKI
(cTn may rise and fall)
Known CKD or ESKD
(baseline cTn may be high)
ACS = acute coronary syndrome; AKI = acute kidney injury; CKD = chronic kidney disease; cTn = cardiac troponin; ESKD = end-stage kidney disease; NSTEMI = non-ST-elevation MI. *cTn >99th 
percentile of upper limit of normal; **cTn <99th percentile of upper limit of normal. †Significant increase in cTn <3 ng/l; ††significant rise of >20% or 99th percentile of upper limit of normal.
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Studies looking at the behaviour of cardiac biomarkers in dialysis 
patients offer different explanations as to how concentrations may 
be affected by treatment, and suggest some differences in behaviour 
between the different types of troponins.15 For example, some studies 
suggest that haemoconcentration may increase troponin levels, 
whereas others suggest that troponin levels may be lower as a result 
of dialysis clearance.
Part of the universal definition of MI states that at least one troponin 
value must be above the 99th percentile upper reference limit.13 
However, chronic, stable, elevated troponin concentrations have 
been demonstrated in the CKD population in the absence of any 
clinical evidence of a myocardial ischaemic event.16 Perhaps the most 
commonly adopted approach to this problem is to look for a change 
of more than 20% between two values taken several hours apart, 
although there is no real evidence to support this strategy and there is 
a potential to underestimate myocardial events.17 
The European Society of Cardiology (ESC) recommends an algorithm 
to rapidly rule in or rule out NSTEMI using high-sensitivity cardiac 
troponin concentrations, regardless of renal function.18 In reality, 
applying this to renal patients presents some issues. A large European 
prospective multicentre study of 4,726 consecutive patients with 
suspected ACS examined the use of high-sensitivity (hs-)cTnI in those 
with and without renal impairment.19 Of the 904 (19%) with renal 
impairment (eGFR <60 ml/min/1.73 m2), only 17% were identified as 
low risk based on troponin concentration <5 ng/l at presentation, 
compared with 56% without renal impairment (p<0.001).19 The positive 
predictive value and specificity when troponin concentrations were 
in the 99th percentile were lower in patients with renal impairment, 
at 50.0%, 95%  CI [45.2–54.8%] and 70.9%, 95% CI [67.5–74.2%]), 
respectively, than in those without any renal impairment (62.4%, 
95% CI [58.8–65.9%] and 92.1%, 95% CI [91.2–93.0%], respectively).19 
However, the data suggest that these elevated troponin concentrations 
in the CKD population should not be completely discounted. 
At 1 year, patients with renal impairment and elevated cardiac 
troponin concentrations >99th percentile had a twofold greater risk 
of a major cardiac event than those with normal renal function.19 
Elevated cardiac troponin concentrations have been associated with 
poor outcomes among both CKD and ESKD patients. A 2014 meta-
analysis of 11 studies, adjusted for coronary artery disease and age, 
demonstrated a threefold increase in mortality with chronically elevated 
cTnT in ESKD patients.3 
A further large multicentre cohort study of 3,254 patients using the 
ESC 0/1-hour algorithm in patients with and without renal dysfunction 
(defined as eGFR <60 ml/min/1.73 m2) found that the prevalence of 
NSTEMI was higher in the 487 patients with renal dysfunction than 
in those with normal function (13% versus 30%).20 That study used 
both hs-cTnT and hs-cTnI. Compared with patients with normal renal 
function, hs-cTnT concentrations in patients with renal dysfunction 
had comparable sensitivity of rule out (100.0% versus 99.2%; p=0.559), 
lower specificity of rule in (88.7% versus 96.5%; p<0.001) and lower 
overall efficacy (51% versus 81%; p<0.001).20 The authors concluded 
that this was likely the result of the lower percentage of patients with 
renal dysfunction who were eligible for rule out compared with patients 
with normal renal function (18% versus 68%; p<0.001).20 In patients 
with eGFR <60 ml/min/1.73 m2, hs-cTnI had comparable sensitivity of 
rule out (98.6% versus 98.5%; p=1.0), lower specificity of rule in (84.4 
versus 91.7%; p<0.001) and lower overall efficacy (54% versus 76%; 
p<0.001) compared with patients with normal renal function.20 This 
also helps highlight the subtle differences between using hs-cTnT and 
hs-cTnI in the renal population. Subsequent attempts at modifications 
of the rule-in and rule-out thresholds did not improve the safety or 
overall efficacy of the algorithm.20 
Acute Coronary Syndrome Biomarker and Acute 
Kidney Injury
AKI is common in patients with ACS. In a large American retrospective 
study, 26.6% of patients diagnosed with ACS also had AKI (defined 
in that study as a rise in serum creatinine of 0.3 mg/dl).21 Prompt 
diagnosis of ACS in patients also diagnosed with AKI is important to 
ensure appropriate, tailored management for both conditions.
Several possible mechanisms play a role in the increase in cardiac 
biomarkers in AKI. During AKI there may be a degree of non-ischaemic 
myocardial necrosis or myocardial injury, as seen with heart failure, 
cardiac arrhythmias and cardiac interventions. Furthermore, conditions 
that may precipitate AKI, such as sepsis and hypotension, may also 
cause a comparable myocardial injury, and hence increase cardiac 
biomarkers (by definition, a type 2 MI).22 
Decreased elimination of biomarkers, due to reasons discussed above, 
may also result in a rise in levels. Deterioration of kidney function with 
evolving AKI and improvement during recovery phase may result in a 
rise and fall of biomarker levels – this may mimic the rise and fall of 
biomarkers seen with MI, leading to a degree of diagnostic uncertainty. 
Standardising patient selection, blood sampling, assays and definitions 
between studies examining cardiac biomarker levels in patients with 
AKI mean data are limited.
In an early study, serum cardiac biomarkers were compared between 
patients with AKI and those with CKD (creatinine 120–200 µmol/l), 
severe CKD (creatinine 200–400 µmol/l) and on haemodialysis.23 
The patients with AKI had severe AKI (creatinine >500 µmol/l), and 
many had multiorgan dysfunction requiring continuous venovenous 
haemodiafiltration. Active ischaemic heart disease was ruled out with 
clinical features, ECG and echocardiogram. Concentrations of cTnT and 
cTnI were highest in patients with AKI. On serial measurements of three 
AKI patients, recovery of renal function was associated with a fall in 
cTnT to undetectable levels.23
In another study of 19 AKI stage 2 and 3 patients, 39 samples were 
obtained at admission, peak creatinine and discharge.1 Patients 
with multiorgan failure, ACS, pericarditis, myocarditis, sepsis, heart 
failure, pulmonary embolism and cardiac arrhythmias were excluded.1 
Concentrations of hs-cTnT were elevated in 32% of patients.1 The 
patients with elevated hs-cTnT were older and had minor ECG 
abnormalities.1 Concentrations of hs-cTnT, hs-cTnI and CK-MB tended 
to fall with AKI recovery and hospital discharge.1 That study helpfully 
demonstrated that, even when removing confounders such as ACS and 
sepsis, AKI still results in elevated cardiac biomarkers.1 
Very interesting observations were made from a large database 
of 17,113 matched cTnT and creatinine values in 10,418 patients 
admitted to a single hospital.2 The cardiovascular disease history of 
the patients was unknown, and 3,108 pairs of results were obtained 
within a short period of time (median 15 hours; interquartile range 
7–25 hours).2 Within that short period, the cTnT values rose and 
190
Acute Coronary Syndrome
E U R O P E A N  C A R D I O L O G Y  R E V I E W
fell with increasing and decreasing kidney function, suggesting 
renal clearance as a cause of the rise and fall rather than cardiac 
injury.2 Concentrations of cTnT increased and decreased with kidney 
function >120 and 5 ml/min, respectively.2 
Conclusion
We have reviewed the interesting and growing literature available on 
the topic of troponin interpretation in kidney patients from AKI through 
to ESKD. Although considerable advances have been made in the use 
of cardiac biomarkers to aid diagnosis, it is clear that a degree of 
caution is required in their application to renal patients. 
In terms of practical clinical implications, a few conclusions can 
be drawn, although these are far from definitive. It is clear that it is 
important not to completely discount high troponin concentrations 
in CKD and ESKD patients. Elevated troponins are associated with 
increased cardiovascular risk, and discounting this means we run the 
risk of mismanaging cardiac risk factors, underinvestigating a very 
high-risk population or, indeed, missing acute events. 
Drawing upon the full combination of biomarkers, ECG, cardiac imaging, 
clinical history and physical examination (and, where appropriate, 
coronary angiography) will be vital in diagnosing and treating patients 
correctly (Figure 1). 
To date, adjusted algorithms for the interpretation of troponin in renal 
patients have been, at best, partially successful. It seems sensible to 
continue to use serial troponins in kidney disease patients as advised 
by the Joint Task Force of the ESC, American College of Cardiology 
Foundation, the American Heart Association and the World Heart 
Federation for diagnosis in patients without kidney disease.24 More 
research is needed to discover new biomarkers and to better use 
the available biomarkers in AKI, CKD and ESKD patients for the early 
diagnosis of and better outcomes after ACS. 
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